Uterine myoma MRI has become the gold standard for characterizing fibroids when ultrasound findings are inconclusive or when patients are being evaluated for uterine-sparing therapies. Unlike transvaginal sonography, which can miss small submucosal lesions or underestimate the burden of disease in large polymyomatous uteri, MRI provides exquisite soft-tissue contrast, accurate volumetric measurements, and reliable mapping of every individual fibroid in relation to the endometrial cavity, serosa, and adjacent organs. For radiology trainees and MRI technologists, mastering this exam is essential because referrals continue to climb year over year.
Fibroids, technically known as leiomyomas, are the most common benign neoplasm of the female pelvis, affecting up to 70 percent of white women and more than 80 percent of Black women by age 50. While many fibroids remain asymptomatic, others cause heavy menstrual bleeding, pelvic pain, bulk symptoms, infertility, and pregnancy complications. The role of MRI is not only to confirm the diagnosis but also to triage patients toward the most appropriate intervention: expectant management, hormonal therapy, myomectomy, uterine artery embolization, MR-guided focused ultrasound, or hysterectomy.
A well-performed pelvic MRI answers four clinical questions in a single twenty-five-minute exam. How many fibroids are present and where is each one located using the FIGO 0 through 8 classification? What is the dominant T2 signal pattern, since hyperintense lesions respond differently to embolization than dark, fibrous ones? Are there features that should raise concern for leiomyosarcoma, the rare but devastating malignant mimic? And finally, is there coexisting adenomyosis, endometriosis, or an adnexal mass that would alter management?
This guide walks through every component of the modern fibroid imaging workup. We will cover the technical protocol, including coil selection, antiperistaltic agents, and the role of dynamic gadolinium-enhanced sequences. We will review the signal characteristics of typical fibroids and the four classic patterns of degeneration: hyaline, cystic, myxoid, and red. We will explain how to map lesions using the FIGO system, how to dictate a report that surgeons actually find useful, and how to recognize the red flags that should prompt consideration of sarcoma.
Throughout, the emphasis will be on practical, exam-relevant knowledge. If you are preparing for the ARRT MRI registry, the ABR core exam, or simply trying to improve your dictation quality, understanding fibroid imaging in depth pays dividends because the same sequences, principles, and pitfalls apply to endometrial pathology, ovarian masses, and deep infiltrating endometriosis. For a broader review of pelvic findings and other anatomical regions, see our overview of common MRI findings across the brain, spine, and joints.
The literature on fibroid MRI has matured significantly over the past decade, with consensus statements from the Society of Abdominal Radiology, the American College of Radiology, and the European Society of Urogenital Radiology. We have drawn on these guidelines, on landmark studies of diffusion-weighted imaging for sarcoma detection, and on practical workflow recommendations from high-volume fibroid centers. The result is a comprehensive yet readable reference you can return to before your next pelvic case.
By the time you finish this article, you should be comfortable protocoling a fibroid MRI from scratch, interpreting the dominant sequences, applying the FIGO classification confidently, distinguishing degeneration from malignancy, and writing a structured report that streamlines surgical planning. Whether you scan two pelvises a week or twenty a day, these skills translate directly into better patient care and more efficient throughput.
Detailed localization of every fibroid before myomectomy or hysterectomy, including FIGO type, distance to endometrium, and proximity to vascular pedicles or ureters in laterally located lesions.
Pre-procedural assessment for uterine artery embolization, evaluating fibroid number, T2 signal, enhancement pattern, and exclusion of pedunculated subserosal lesions that may detach after infarction.
Screening for MR-guided focused ultrasound candidacy, requiring accessible acoustic window, T2 hypointense signal, no bowel in beam path, and absence of abdominal wall scars exceeding two centimeters.
Evaluation of rapidly enlarging masses, postmenopausal growth, or atypical imaging features, using diffusion-weighted imaging and ADC values to stratify risk for leiomyosarcoma versus benign degeneration.
Characterization of submucosal and intramural fibroids distorting the endometrial cavity, often performed alongside hysterosalpingography to guide reproductive endocrinology decisions about myomectomy timing.
A robust uterine myoma MRI protocol begins with patient preparation. Patients are asked to fast for four hours when intravenous contrast is planned, to empty the bladder partially before scanning, and in many centers to receive a single intramuscular or intravenous dose of glucagon or hyoscine butylbromide to suppress bowel peristalsis. Without antiperistaltic medication, motion artifact from small bowel and rectum can obscure the uterine contour and degrade the dynamic post-contrast series, which is the single most important sequence for surgical planning.
Coil selection matters more than most trainees realize. A multi-channel phased-array surface coil placed over the pelvis, anchored from symphysis to iliac crest, delivers signal-to-noise dramatically better than a body coil. At 3 Tesla the gains in spatial resolution allow visualization of fibroids as small as three millimeters, which is clinically relevant for submucosal lesions causing infertility. Patients are positioned supine, feet first, with arms at the sides to reduce shoulder discomfort during the half-hour exam.
The core sequence stack includes high-resolution T2-weighted fast spin-echo images in three orthogonal planes prescribed along the long and short axes of the uterus. Axial and sagittal T1-weighted images without fat suppression establish baseline signal and identify hemorrhagic fibroids or red degeneration. A T1 fat-saturated sequence helps distinguish fat-containing lesions like lipoleiomyomas from blood products, which behave very differently on chemical shift imaging.
Diffusion-weighted imaging has become indispensable. A b-value series of 0, 400, and 800 or 1000 with corresponding ADC mapping helps differentiate cellular leiomyomas, which can show mild restriction, from leiomyosarcomas, which classically demonstrate marked restriction with ADC values below 0.9 times ten to the negative three millimeters squared per second. While there is overlap, combining DWI with T2 signal and post-contrast features substantially improves specificity for the rare malignant case.
Dynamic contrast-enhanced imaging with a fat-saturated three-dimensional gradient-echo sequence is acquired before, during, and after gadolinium injection. Typical timing includes arterial, venous, and delayed phases at roughly 25, 65, and 180 seconds. The arterial phase reveals the vascular supply and aids embolization planning, while delayed images show the extent of viable tumor versus necrosis. Areas that fail to enhance after treatment correspond to successful ablation.
Field strength influences protocol choices. At 1.5 Tesla, longer T2 echo trains and thicker slices may be needed to achieve adequate signal-to-noise. At 3 Tesla, susceptibility from bowel gas and metallic IUDs becomes more problematic, and parallel imaging combined with shortened echo times helps mitigate artifact. Either field strength is acceptable for routine fibroid imaging when protocols are optimized; the bigger determinants of quality are coil choice, antispasmodic use, and technologist attention to motion. For deeper context on what these protocols can reveal across body regions, review our article on what MRI can detect across conditions and diagnostic capabilities.
Finally, special situations call for protocol modification. Pregnant patients with suspected red degeneration undergo non-contrast exams limited to T2 and DWI. Patients with severe claustrophobia may be candidates for wide-bore scanners with abbreviated protocols. Patients with prior embolization need a post-treatment baseline that emphasizes delayed enhancement to assess infarction percentage, a key predictor of symptomatic improvement at six months.
The classic non-degenerated leiomyoma appears as a well-circumscribed, round or oval mass that is markedly hypointense on T2-weighted images compared with adjacent myometrium. On T1-weighted sequences it is isointense to muscle. After gadolinium, enhancement is variable but usually similar to or slightly less than surrounding myometrium, reflecting the dense collagenous matrix and lower vascular density of mature fibroids.
A peripheral pseudocapsule of compressed myometrium and dilated vessels often produces a thin T2 hyperintense rim, which is helpful for distinguishing a fibroid from focal adenomyosis. This rim corresponds to the surgical plane that gynecologists exploit during enucleation. Recognizing these baseline features is essential because every degenerative subtype represents a deviation from this default appearance, and surgeons rely on the report to anticipate dissection difficulty.
Hyaline degeneration is the most common form, affecting roughly 60 percent of fibroids, and produces only subtle T2 signal changes without enhancement abnormalities. Cystic degeneration shows discrete T2 hyperintense fluid spaces that do not enhance, mimicking necrosis but typically with a smooth, rounded morphology. Myxoid degeneration creates striking T2 hyperintensity with progressive late enhancement, sometimes raising concern for sarcoma until the clinical context is considered.
Red or carneous degeneration occurs classically during pregnancy and presents with a peripheral T1 hyperintense rim from hemorrhagic infarction, low T2 signal, and absent enhancement. Patients describe acute focal pain. Recognizing this pattern prevents unnecessary surgical intervention, since red degeneration resolves with supportive care, analgesia, and watchful follow-up imaging at six to twelve weeks postpartum.
Cellular leiomyomas are a benign variant with dense, packed smooth muscle cells, less collagen, and mildly elevated cellularity that produces intermediate to high T2 signal with avid post-contrast enhancement. They can show mild diffusion restriction and occasionally raise concern for malignancy. ADC values typically remain above 1.0, and the absence of necrosis, hemorrhage, or irregular margins helps distinguish them from leiomyosarcoma.
Lipoleiomyomas contain mature adipose tissue and demonstrate macroscopic fat on T1 imaging, with signal loss on fat-suppressed sequences. They are clinically benign, often incidental, and important to recognize because their imaging appearance overlaps with ovarian dermoids when peripherally located. Chemical shift imaging, in-phase and out-of-phase sequences, can confirm fat content and prevent unnecessary workup or biopsy.
Fibroids that are T2 hyperintense before uterine artery embolization respond more dramatically than T2 hypointense lesions, with greater volume reduction at six months. Conversely, very dark fibroids on T2 may have already undergone hyaline degeneration and offer less room for improvement. Always include dominant signal characterization in your report.
The greatest clinical anxiety in fibroid imaging is missing a leiomyosarcoma masquerading as a benign fibroid. While sarcomas are rare, accounting for less than one percent of presumed fibroids in surgical series, the consequences of morcellating an unsuspected malignancy during minimally invasive surgery are severe, with peritoneal dissemination and dramatically worsened survival. MRI plays a critical role in flagging suspicious lesions before the operating room.
Classic features that should raise concern include rapid growth in a postmenopausal woman, large size above ten centimeters with heterogeneous internal architecture, intermediate to high T2 signal with central T2 hyperintense necrosis, irregular or infiltrative margins, restricted diffusion with ADC values consistently below 0.9, and lack of the typical pseudocapsule. Pooled studies suggest that the combination of T2 heterogeneity, marked diffusion restriction, and early arterial enhancement carries the highest positive predictive value.
However, no single feature is diagnostic. Cellular leiomyomas, myxoid degeneration, and red degeneration can each mimic some sarcoma features. The wise radiologist describes the constellation of findings, assigns a probability rather than a binary answer, and recommends gynecologic oncology consultation when concern is high. Tissue sampling before morcellation, with techniques like image-guided biopsy or in-bag morcellation, has emerged as a pragmatic compromise in equivocal cases.
Beyond sarcoma, other mimics deserve consideration. Focal adenomyosis can simulate an intramural fibroid but typically demonstrates poorly defined margins, T2 hyperintense linear striations or microcysts, and absence of a pseudocapsule. Adenomyomas, the focal mass-forming variant, are even more confusing and may require careful comparison of the dominant signal pattern and border characteristics. Solid ovarian masses adherent to the uterus, including fibromas and Brenner tumors, can be mistaken for pedunculated subserosal fibroids when the connecting stalk is poorly seen.
The bridging vessel sign, in which prominent vessels course from the uterus into the pedicle of a presumed pedunculated fibroid, helps confirm uterine origin. Conversely, identification of a separate normal ovary on the side of the mass shifts the diagnosis toward fibroid rather than ovarian neoplasm. Multiplanar T2 imaging and careful tracing of structures across slices is the only reliable way to resolve these questions.
Other pitfalls include intravenous leiomyomatosis, a rare benign condition in which smooth muscle tumor extends into pelvic veins and occasionally up the inferior vena cava, and benign metastasizing leiomyoma, in which histologically benign fibroid tissue appears in distant sites such as the lungs. Both are exceedingly rare but worth knowing because they highlight the limitations of imaging alone and reinforce the importance of clinical and pathologic correlation in atypical presentations.
Finally, post-treatment changes need to be interpreted in context. After uterine artery embolization, fibroids show decreased enhancement, increased T1 signal from coagulation necrosis, and progressive volume loss over six to twelve months. After focused ultrasound, the treated zone is non-enhancing with sharp borders, and the non-perfused volume on immediate post-treatment imaging predicts long-term outcome. Recognizing expected post-treatment appearances prevents misinterpretation as residual or recurrent disease.
A structured fibroid MRI report transforms a wall of measurements into actionable surgical guidance. The opening line should state the indication, the technique including field strength and contrast administration, and any limitations such as motion artifact or incomplete bowel suppression. A brief comparison statement to prior imaging, when available, sets the stage for any growth assessment that follows.
The body of the report should begin with global uterine parameters: orientation, anteverted or retroverted; flexion; three-axis measurements; junctional zone thickness; and endometrial appearance. From there, move to the dominant fibroid, providing FIGO type, anatomic location described in clock-face or quadrant terms, three-axis measurement, volume, T2 signal, T1 signal, enhancement pattern, diffusion characteristics, and any degeneration. Then list additional fibroids in descending order of size with abbreviated descriptors.
Treatment-oriented impressions are far more valuable than generic lists. Comment on candidacy for hysteroscopic resection if FIGO 0 to 2 lesions are present, for myomectomy if FIGO 3 to 6 lesions dominate, for embolization based on number, T2 signal, and pedunculation status, and for focused ultrasound based on accessibility, signal, and beam path obstacles. Note any feature that argues against minimally invasive morcellation, especially in older patients.
Communication with the referring gynecologist or interventional radiologist closes the loop. Many centers have developed multidisciplinary fibroid clinics where imaging, gynecology, and interventional radiology jointly review cases. Participating in those meetings, even briefly, dramatically improves the quality of subsequent reports because radiologists learn which details actually influence decisions and which are noise. For trainees, observing a fibroid case from imaging through intervention is one of the most instructive experiences in body MRI.
Don't underestimate the value of comparison studies. When prior MRI is available, document interval growth or stability of each significant lesion, since rapid growth changes management entirely. Use the same FIGO labeling between exams so individual fibroids can be tracked. Many PACS systems now support hanging protocols that align prior and current studies side by side, simplifying this comparison and ensuring nothing slips through the cracks. For technologists, see our resource on how to become an MRI technician for career context.
Reports should also acknowledge incidental findings. Adnexal cysts, hydrosalpinx, deep infiltrating endometriosis, ureteral hydronephrosis, and lumbosacral abnormalities are all routinely seen and deserve mention. Use measured language; not every simple cyst needs follow-up, and labeling benign incidental findings as concerning generates downstream cost and patient anxiety without benefit.
The closing impression should be concise, ideally three to five lines, addressing the clinical question directly. Begin with the most important finding, provide the FIGO mapping summary, mention any concerning features and their probability of malignancy, and end with a specific recommendation. A good fibroid report reads like a consult note rather than an inventory, and surgeons quickly learn which radiologists deliver that quality.
Practical preparation for fibroid MRI begins long before the patient arrives. Technologists should review the requisition, confirm contrast eligibility by checking renal function and gadolinium allergy history, and verify that any antiperistaltic agent is approved and available. For premenopausal patients, scheduling within days 7 to 14 of the cycle minimizes hormonal influence on endometrial appearance, though this is not always achievable and should not delay urgent imaging.
Patient communication is undervalued. Explaining the duration, the importance of holding still, and the sensations associated with gadolinium injection reduces anxiety and motion artifact. For claustrophobic patients, offering prone positioning, mirrored prism glasses, or low-dose oral anxiolytics under physician direction can convert an aborted exam into a diagnostic study. Music through MRI-compatible headphones helps remarkably with longer protocols.
Image review during the exam allows the technologist to recognize artifact and add sequences as needed. If the initial T2 sagittal shows motion, repeating after a deeper inspiration coaching or a second dose of antispasmodic is faster than recalling the patient. If a suspicious mass appears, alerting the radiologist before the patient leaves enables protocol extension with diffusion at higher b-values or delayed contrast phases. Real-time review elevates exam quality dramatically.
For trainees preparing for boards, fibroid MRI is a high-yield topic. Expect questions on the FIGO classification, on T2 signal patterns and their treatment implications, on sarcoma red flags, on degeneration types and their imaging features, and on post-treatment appearance. Use practice questions and case banks to build pattern recognition, since fibroid imaging rewards repeated exposure more than memorization of facts. For visual reference, compare your interpretations against examples of normal MRI images across body regions.
Workflow efficiency matters in busy practices. Templates with structured fields for each fibroid, voice macros for common findings, and PACS measurement tools that auto-populate the report can cut dictation time by 40 percent. The savings come without sacrificing quality if the templates are designed thoughtfully and updated as practice evolves. Investing time in template refinement pays back over hundreds of subsequent cases.
Finally, continuous learning sustains expertise. Attend the annual Society of Abdominal Radiology fibroid course, follow the major journals for emerging evidence on sarcoma stratification, and participate in tumor boards or fibroid clinics. The literature on MR-guided focused ultrasound continues to mature, with newer techniques like volumetric ablation and intermediate-temperature treatment changing the imaging workflow. Staying current ensures your reports remain clinically relevant.
Above all, remember that every report represents a patient making decisions about her body. The difference between a vague report and a precise one is often the difference between an unnecessary hysterectomy and a successful uterine-sparing intervention. Take the extra two minutes to characterize the dominant fibroid completely, to comment on treatment options, and to acknowledge uncertainty when present. That craft is what separates competent radiologists from outstanding ones.